Miguel Valderrábano is Chief of Cardiac Electrophysiology at the Houston Methodist Hospital, where he holds the Lois and Carl Davis Centennial Chair, and a Professor of Medicine at Weil Cornell Medical College, Cornell University. 

Miguel Valderrábano attended medical school in Madrid, Spain, graduating in 1994. Thereafter, he pursued further training in the United States, completing his Internal Medicine training in the UCLA-VA program in Los Angeles, and Cardiology and Cardiac Electrophysiology training at Cedars-Sinai Medical Center, where he also completed a basic research fellowship funded by the American Heart Association, and was awarded First Place in the Young Investigator Award competition of the American College of Cardiology. Following training, he joined the faculty at the UCLA David Geffen School of Medicine, where he continued his basic and clinical research as Assistant Professor of Medicine. In 2006, he became the Director of the Division of Cardiac Electrophysiology at the Houston Methodist Hospital, and Associate Professor of Medicine at Weil Cornell School of Medicine. His research evolved from basic mechanisms of electrical propagation and cardiac fibrillation using optical mapping in ex vivo hearts and cultured cardiomyocytes to more translational and clinical aspects of cardiac electrophysiology. He pioneered the procedure of retrograde ethanol infusion in the vein of Marshall as an ablation tool in the treatment of atrial fibrillation and flutter, and, funded by the NIH, took the procedural technique from conception to animal validation, and to a completed multi-center clinical trial. He also expanded the retrograde venous ethanol infusion technique to ablation of refractory ventricular tachycardia, first for LV summit arrhythmias, and more recently, to perform multi-vein, multi-balloon ablations of complex substrates of ventricular tachycardia. He is also known for his contributions in left atrial appendage occlusion procedures for stroke prevention in atrial fibrillation. His leads a clinical and research group with projects spanning the entire spectrum from bench research in engineered heart tissues, to translational models in large animals, and to clinical trials in procedural cardiac electrophysiology.